Robust U.S. Biosimilar Market Will Encourage Competition and Lower Prescription Drug Costs for Patients
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition